We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on ...

Tata Consultancy Services (TCS) will open its office in Visakhapatnam within the next three months, IT Minister Nara Lokesh said, adding that the IT major will initially begin operations from a ...

Ei­sai and Bio­gen scored an ap­proval for once-month­ly IV main­te­nance dos­ing of their Alzheimer’s drug Leqem­bi, as part of what they’ve said is an on­go­ing … ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab-irmb) has been approved by the US Food and Drug Administration (FDA) for monthly maintenance dosing. The anti-amyloid drug was ...

Credit: Chinnapong/Shutterstock. The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen’s Leqembi (lecanemab-irmb) for maintenance ...

Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing regimen for Leqembi (lecanemab). Already approved ...

Additionally, a monthly dosing schedule for Leqembi “may be easier for patients and care partners to continue treatment,” potentially helping with the drug’s uptake, according to Eisai’s press ...

(Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday. The drug ...

On January 15, when the rest of Andhra Pradesh celebrated Sankranti, the employees of Vizag Steel stood firmly outside the Visakhapatnam steel plant in protest. They demanded their pending salaries—In ...